Armata Pharmaceuticals, Inc. 8-K

Summary

Clinical development milestone for AP-SA02. FDA agreed that Phase 2a diSArm safety and efficacy data support advancing the intravenous bacteriophage candidate to a Phase 3 superiority study for complicated Staphylococcus aureus bacteremia. The study is anticipated to start in H2 2026; it will compare AP-SA02 with the current standard of care. FDA provided recommendations on study design and the future Biologics License Application, including comments on manufacturing and controls. Armata has submitted a request for Qualified Infectious Disease Product designation.

Investor Takeaways

• Watch for Phase 3 initiation in H2 2026 and subsequent trial progress; the primary endpoint is clinical response at the end of best available antibiotic therapy and 28 days later.